Discovers new medicines for cancer treatment. Develops therapies targeting various types of cancer. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
Average growth of 10% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $886.1M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 34% — still a thick cushion, though costs have been eating into it lately.
Over the last 5 years, sales grew about 10% a year on average.
There is $1.1B in the vault; even if every debt were paid off, $886.1M would remain.
Our checks did not surface a specific risk to flag here. That is not the same as there being none.
On our five-subject report card, EXEL sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: EXEL is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.